Kalohexis Files Confidential IPO to Expand Obesity Portfolio

Kalohexis has filed confidentially for an initial public offering (IPO) with the US Securities and Exchange Commission (SEC) to support its therapies targeting obesity and cancer cachexia. The company, which spun out from Endevica Bio in March 2026, has two clinical-stage programs: mifomelatide and 710GO. Currently, the estimated sales in the obesity market could reach $173.5 billion by 2031 across major markets. This move reflects the growing trend of biotech companies going public in 2026, which could present new investment opportunities for ordinary investors.